Lifecycle Stage Design. Following a comparative assessment, which determined that there would be benefits, the … 1.4 The main changes from the previous standard and advice note are summarised as follows: i This standard combines and supersedes the previous standard TD 22/92 and the advice note TA 48/92. Welcome to the DMRB Find a document. The patients did not show any significant response to the treatment, with exception of one patient achieving a complete response [74]. The biologic activity of IL-3 is not limited only to the hematopoietic system, but it extends also to the endothelial lineage, where IL-3 acts as a stimulator of endothelial cell proliferation [8]. Only over-expressing CD123 patients with RAEB are still alive among the 7 RAEBs. In this context, CD123 expression at the level of CD34+ cells isolated from various sources of hematopoietic cells (fetal liver, cord blood, bone marrow and peripheral blood) was studied. Blood 2012, 120: Abstract 3598. Article  Both whole leukemic AML blasts and CD34+CD38-CD123+ leukemic stem cells were sensitive to CSL362-induced ADCC [62]. Another phase I study of CSL362 (anti-IL-3Rα/CD123 monoclonal antibody) in patients with CD123+ acute myeloid leukemia in complete remission or complete remission with incomplete platelet recovery at high risk for early relapse is ongoing (NCT01632852, Clinical Trials Gov). Sato an coworkers showed that a part of human and cord blood CD34+ cells express CD123 and the growth of these cells in the presence of cytokines stimulating their proliferation resulted in an increased CD123 expression [13]. http://creativecommons.org/licenses/by/2.0, http://creativecommons.org/publicdomain/zero/1.0/. Some of these compounds entered phase I clinical studies (Table 1) aiming to define the safety profile and to have the first indications about a possible therapeutic impact of CD123 targeting in patients with advancer AMLs. This review analyzes the studies indicating that CD123 … Subsequent studies on IL-3Rα in AMLs have been performed with the specific aim of defining the possible biologic effects induced by IL-3Rα overexpression in leukemic blasts, the AML subsets particularly associated with the receptor hyperexpression and the receptor expression on leukemic stem cells. Blood 2011,117(16):4243–4252. Leukemia 2004,18(2):219–226. 10.1182/blood-2005-02-0540, Yalcintepe L, Frankel AE, Hogge DE: Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphteria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice. A reagent corresponding to these properties is represented by the anti-CD123 mAb 7G3 capable of inhibiting IL-3-mediated proliferation of leukemic cell lines [60]. 1.8 The current revision has been based on feedback received from users of the 2002 Standard and is intended to further simplify and improve the process. 2. CD123 is the 70 kD transmembrane α chain of the IL-3 receptor. Revision 0 dated November 2019. Google Scholar, Shao K, Calvo KR, Grouborg M, Temhore PR, Kreitman RJ, Stetler-Stevenson M, Yuan CM: Distinguishing hairy cell leukemia variant from hairy cell leukemia: development and validation of diagnostic criteria. For implementing road safety audits on highway schemes on all-purpose trunk roads and motorways. 2/12 5. DMRB Volume 4, Section 2, Part 1, HA 103/06 Vegetative Treatment Systems for Highway Runoff 3. Revision 2 … Discipline Road Layout. 10.3109/08977194.2011.649919, CAS  DMRB Volume 4, Section 2, Part 3, HD 33/16 Design of Highway Drainage Systems 4. 10.1002/iub.350. Further significant changes have been made to the DMRB drainage standards, such as the update of HD43/04 (Drainage Data Management System for Highways) into CD535 (Drainage Asset Data and Risk Management), which incorporates IAN147/11 and a number of guidance documents into the DMRB. ) linked to human interleukin 3 (IL3) in cymolgous monkeys. In 2009, Djokic and coworkers reported a detailed analysis of CD123 expression on B-ALLs. In a recent study representing the largest series of these patients (43 patients) never reported in the literature, it was observed a median overall survival of about 8-9 months following treatment with standard chemotherapeutic regimens used for AMLs and ALLs; the median overall survival of patients undergoing allogeneic stem cell transplantation was about 23 months [29]. Through the anti-CD16 moiety this fusion antibody is able to bind NK lymphocytes and monocytes/macrophages [68]. Junction Design Compliance – DMRB CD123 (Revision B) Section/Paragraph Standard Priority Junction Design Compliance Signal Controlled Junction Design Compliance Chapter 1: Scope 1.1 This document shall be used for the geometric design of at-grade priority junctions and signal-controlled junctions. This means that the relationship between NO x and NO 2 at the roadside has changed from that currently used in the DMRB model. Interestingly, the fusion of the DT to a variant of IL-3 with increased binding affinity (IL-3[K116W]) resulted in a fusion protein, DT388IL-3[K116W] significantly more active than DT388IL-3 in mediating leukemic cell killing [55]. In the next decade, advances in patient selection and drug design should establish a role for CD123 targeted therapy in hematologic malignancies. 10.3324/haematol.2008.000299, Hassanein N, Alcancia F, Perkinson K, Buckley P, Lagoo A: Distinct expression patterns of CD123 and CD 34 on normal bone marrow B-cell precursors (“hematogenes”) and B lymphoblastic leukemia blasts. The first allows a limited number of Restricted Foundation Designs to be applied for Foundation Classes 1, 2 and 3 and is particularly intended for use on schemes of limited extent. Some researches have revealed that CD123 is a marker of leukemia stem cells, which indicates that the eradication of CD123 cells may prevent relapse of leukemia. Design Revision 2 – March 2017 4.2.14 One of the DMRB Stage 2 recommendations was to consider the potential benefits of a compact form grade separated junction at Newtonmore. In fact, a proportion of CD34+/CD38-/CD123+ cells greater than 15% in AML patients with unfavourable karyotype was associated with a lack of complete remission; furthermore, the presence of more than 1% of CD34+/CD38-/CD123+ cells had a negative impact on disease-free survival and overall survival [47]. Blood 1997,89(3):842–852. The same compound SL-401 was evaluated also in the context of a phase I clinical study involving eight patients with blastic plasmocytoid dendritic cell neoplasms [30]. Importantly, IL-3 is required for an efficient in vitro generation of plasmacytoid dendritic cells [26]. 10.1002/stem.170265, Manz MG, Miyamoto T, Akashi K, Weissman IL: Prospective isolation of human clonogenic common myeloid progenitors. Another recent study reported the development of a novel conjugate of single-chain Fv antibody fragments specific for CD123 with an anti-CD16 antibody. A single cycle of 5-days treatment with this agent at 12.5mcg/kg IV over 15 minutes elicited a pronounced anti-tumor response inducing clinical remissions in most patients lasting several months to over a year [30]. Google Scholar, Buelens C, Bartholome EJ, Amraoui Z, Boutriaux M, Salmon I, Thielemans K, Willems F, Goldman M: Interleukin-3 and interferon beta cooperate to induce differentiation of monocytes into dendritic cells with potent helper T-cell stimulatory properties. Blood 2013, 122: Abstract 360. Part 7 Noise (HA, 2015). Many studies have explored the expression of CD123 at the level of repopulating stem cells and of various subpopulations of hematopoietic progenitor cells. Some of these compounds were introduced in clinical studies in the context of phase I studies in AML and BPDCN patients with promising results. Role of Foundation 7 3. 10.1182/blood.V99.3.993. 10.1309/AJCPO4DS0GTLSOEI, Constan-Smith E, Song G, Clark C, Key L, Liu P, Mehrpooya M, Stow P, Su X, Shurtleff S, Pui CH, Downing JR, Campana D: New markers for minimal residual disease detection in acute lymphoblastic leukemia. DMRB CD 109 - Highway link design. DMRB guidance updates relevant to the EIA 11 2.1 Overview 11 3. Series. In spite these limitations, several clinical trials have shown that high-sensitivity measurement of residual disease burden (minimal residual disease, MRD) during and after treatment can be performed and may be used to try to improve clinical outcomes by guiding to additional clinical interventions of some patients in complete clinical remission [49]. Cohen KA, Liu TF, Cline JM, Wagner JD, Hall PD, Frankel AE: Toxicology and pharmacokinetics of DT This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. Lee EM, Yee D, Busfield S, Vairo G, Lock R: A neutralizing antibody (CSL362) against the interleukin-3 receptor alpha-chain augments the efficacy of a cytabarine/daunorubicin induction-type therapy in preclinical xenograft models of acute myelogenous leukemia. Sato N, Caux C, Kitamura T, Watanabe Y, Arai K, Banchereau J, Miyajima A, et al. Traffic and Economic Assessment 6.1 Introduction 6.1.1 The purpose of this chapter is to document the development of a … According to these observations, these authors concluded that while in normal B cell precursors a discordant pattern of CD123 and CD34 antigen expression was observed, in B-ALL blasts a concordant pattern of expression of these two antigens was observed [37]. Only 14.4%, 18.8%, 4.7% and 0% of respectively all, AML, ALL and RAEB patients demonstrated LIM without CD123 over-expression. 10.1111/j.1600-065X.2012.01164.x, Article  Find documents by disciplines. Revision 2 DMRB Volume 5 Section 2 GG 119 Revision 2. An initial study by Munoz and coworkers, based on the analysis of a small number of patients, provided evidence that B-ALL express CD123, while T-ALLs were CD123-negative [31]. Ref 4.I replaces previous Ref 1.I and 5.I. Major Road 7.5 Drivers approaching a major/minor priority junction along the major road approaches shall be able to see the minor road entry from a distance corresponding to the Desirable Minimum Stopping Sight Distance (SSD) for the design speed of the major road, as described in TD 9 (DMRB 6.1.1). CD123 or interleukin-3 (IL-3) receptor α chain is expressed in a wide variety of hematologic malignancies such as blastic plasmacytoid dendritic cell neoplasms, AML, B-lymphoblastic leukemia/lymphoma, hairy cell leukemia, and a subset of CLL with strong CD11c expression. In a subsequent study Munoz and coworkers have performed a screening on IL-3Rα expression in hemolymphopoietic malignancies provided evidence that this membrane receptor is very frequently expressed in B-ALL and AML [31]. This DT388IL-3 was shown to be toxic for leukemic blasts [55] and in vivo studies have shown that it is well tolerated up to 100 ug/Kg [56, 57]. CAS  Among the 56 patients undergoing long-term follow-up, 10 shifts (17.9%) and 3 inversed shifts (5.4%) were observed in the CD123 expression. 10.1182/blood-2012-11-459347. (DMRB 7.1.1). Frankel AE, Woo JH, Mauldin JP, Carraway HE, Frankfurt O, Forman SJ, et al. Clin Cancer Res 2006,12(4):1284–1291. Cookies policy. A complete index is maintained in the Design Manual for Roads and Bridges index - GG 000. a DESIGN MANUAL FOR ROADS AND BRIDGES VOLUME 12 TRAFFIC APPRAISAL OF ROADS … Revision 1 - January 2019 - includes a very minor change to the scope section. Frankel AE, McCubrey JA, Miller MS, Delatte S, Ramage J, Kiser M, Kucera GL, Alexander RL, Beran M, Tagge EP, Kreitman RJ, Hogge DE: Diphteria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias. These AMLs were also characterized by the co-expression of receptors for endothelial growth factor [41]. Following a … Leila Mekkaoui, Celine Rassart, Laurence Rozen, Anne Janssens, Dominique Bron, Alina Ferster, Brigitte Cantinieaux; Use of CD 123 Expression on Blasts from AML, ALL and RAEB As Minimal Residual Disease Marker. Related … The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. The nomenclature of BPDCN was adopted in 2008 by the World Health Organization (WHO) classification after the analysis of its main immunophenotypic, molecular and functional properties, such as pronounced CD123 expression, TCL1 expression and production of type I IFN, all suggesting a close link and a pathogenetic relation to the plasmocytoid dendritic cell lineage. Demoulin S, Roncarati P, Delvenn P, Hubert P: Production of large numbers of plasmocytoid dendritic cells with functional activities from CD34+ hematopoietic progenitor cells: use of interleukin-3. In fact, Du and coworkers have isolated CD34+/CD38- cells from three Fanconi anemia patients: Starting from these cells IL-3Rα+ and IL-3Rα- subpopulations and only the positive population was able to initiate the development of a leukemic process when inoculated into immunodeficient mice [48]. J Clin Invest 1993,91(6):2887–2892. Frankel AE, Konopleva M, Hogge D, Rizzieri D, Brooks C, Cirrito T, et al. Bridges, Revision 0 2. CD123 associates with CD131, the 120-140 kDa Common β chain to form the IL-3 Receptor Complex. Nederby L, Hokland P, Brown G, Hansen M, Nyvold CG, Roug AS: Unraveling the leukemic nature of hMICL and CD123 expressing cells in acute myeloid leukemia. CD123 seems actually represent one of the most robust markers to follow MRD with FCM, in AML, ALL and RAEB. In vitro and in vivo studies supported a greater activity of CSL362, compared to the native 7G3 mAb, against CD123+ leukemic cells [60]. 9 (DMRB 6.1.1.2.2). Thus, Buelens and coworkers showed that monocytes cultured with IL-3 and IFN-beta give rise to a population of dendritic cells displaying many properties of plasmacytoid DCs and highly expressing CD123. Additional studies will be required to assess the role of these CD123-targeting drugs, not only when used alone, but also in combination with standard anti-leukemic drugs in the treatment of various leukemic cionditions. Del Giudice and coworkers have explored in detail the expression of CD123 in neoplastic cells derived from 59 patients with B-cell disorders with circulating hairy or villous lymphocytes: CD123 was expressed on hairy cell leukemia, but not on the variant form of hairy cell leukemia and splenic lymphoma with villous lymphocytes [32]. This fusion antibody exhibits several interesting properties: (a) it exhibits increased target cell-binding affinity; (b) it possesses increased stability due to increased serum half-life; (c) it is able to achieve T-cell-mediated target cell killing [66]. CAS  Blood 1997,90(8):3005–3017. Of these 30 markers, 22 were differentially expressed in ALL cases compared to CD19+CD10+ B-cell progenitors; particularly, CD123 was markedly more expressed in the majority of cases on B-ALL blasts, compared to normal B cell progenitors [38]. Brit J Haematol 2013,161(3):389–401. Another recent study showed that the positivity for CD123 was essential for distinguishing both HCL and HCL-variants from other B-cell chronic lymphoproliferative disorders; furthermore, the positivity for CD123 was essential for distinguishing HCL from HCL-variant [34]. The designs are conservative, making allowances for uncertainty in material performance and in layer thickness. Archive this sheet as appropriate. Correct reference is CD 169. Blood 2011,117(23):6267–6276. PubMed  Testa, U., Pelosi, E. & Frankel, A. CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies. These observations have suggested that CART 123 could represent a novel valuable conditioning regimen prior to hematopoietic cell transplantation [72]. Current Supplement. Methods: Ninety-seven patients suffering from hematologic malignancies including69 AMLs, 21 ALLs (18 B-ALLs and 3 T-ALLs) and 7 RAEBs were retrospectively analyzed in regard to CD123 (clone-FITC 763, BD Pharmingen) and other LIM expression measured by flow cytometry (FCM) on myeloid and lymphoid blasts from 2011 to 2014. Nievergall E, Ramshaw HS, Yong A, Biondo M, Busfield SJ, Vairo G, Lopez AF, Hughes TP, White DL, Hiwase DK: Monoclonal antibody targeting IL-3 receptor alpha with CSL362 effectively depletes CML progenitor and stem cells. CD123 was also measured on B-precursors. Reference should be made to DMRB 11.2.1 and 11.2.2 when carrying out an air quality assessment as these document the principles of environmental assessment. Accepted. Steve Cox (pictured), principal consultant at Ramboll, gives Highways his expert insights into the drainage aspects to Highways England's update to the Design Manual for Roads and Bridges (DMRB). © 2021 BioMed Central Ltd unless otherwise stated. In this context, initial studies were focused to develop a IL-3R targeting agent besed on the natural ligand IL-3. Design manual for roads and bridges (DMRB) 11.3.7. CD123 does not transduce intracellular signals upon binding IL-3 and requires the β chain for this function. FCM was performed on 5 and 10-colour flow cytometers with extensive panels to precise leukemia-associated aberrant immunophenotype (LAIP) and blast populations were identified by CD45 vs. side scatter characteristics. Cytokine Growth Fact Rev 2013,24(3):189–201. Jin and coworkers used another approach using a neutralizing anti-IL-3Rα mAb (7G3); ex vivo treatment of CD34+ bone marrow cells elicited a moderate inhibitory effect on the SCID-repopulating capacity (a decrease of about 30% of the engrafting capacity was observed following incubation of bone marrow cells with this antibody). Using AMl cells labeled with this modified antibody it was possible to determine the sites of engraftment of leukemic cells into immunodeficient mice [61]. Other recent studies have addressed the potential utility of the detection of CD123+/hMCL+ cells for the monitoring and for the study of MRD in FLT3-ITD+ AML patients. 10.1172/JCI116534, Woodcock JM, Bagely CJ, Zacharakis B, Lopez AF: A single tyrosine residue in the membrane-proximal domain of the GM-CSF, IL-3 and IL-5 receptor common beta chain is necessary and sufficient for high affinity binding and signalling by all three ligands. Revision 2 - Aug 2020 - Revision 2 (August 2020) To correct issue with incorrect reference being added to clause 2.4 NOTE 2 … https://doi.org/10.1186/2050-7771-2-4, DOI: https://doi.org/10.1186/2050-7771-2-4. Finally, Tettamanti and coworkers have reported a different approach for targeting CD123 based on the transduction of cytokine-induced killer (CIK) cells with a retroviral vector encoding an anti-CD123 chimeric antigen receptor [70]. Publisher Information Highways England. A new NO x to NO 2 calculator, is available as a spreadsheet. Revision 2 (February 2020) Additional update to informative references. It is of interest to note that in mice treated with CSL362 ADCC-facilitated lysis of CD123+ leukemic cells was mediated not by mouse NK cells, but also by the few CML patients’ autologous NK cells [65]. Withdrawn. Interestingly, in the majority of B-ALL patients, CD123+/CD34+ cells were observed post-chemotherapy [37]. 10.1038/sj.leu.2403224. Sun Q, Woodcock JM, Rapoport A, Stomski FC, Korpelainen EI, Bagley CJ, Goodall GJ, Smith WB, Gamble JR, Vadas MA, Lopez AF: Monoclonal antibody 7G3 recognizes the N-terminal domain of the human interleukin-3 (IL-3) receptor alpha-chain and functions as a specific receptor antagonist. Blood 2013,122(21):abstract nr 64672. Taussig DC, Pearce DJ, Simpson C, Rohatiner AZ, Lister TA, Kelly G, Luongo JL, Danet-Desnoyers GA, Bonnet D: Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia.